Il Dong Pharmaceutical Co., Ltd.

Changmok Oh

Gunhee Kim

Jin Hee Lee

Kyung Mi An

Te-ik Sohn

Yearin Jun

Jung Ho Kim

Jeong-Geun Kim

Hong Chul Yoon

Jung-eun Park

Min Whan Chang

Woo Jin Jeon

Da Hae Hong

Changhee Hong

Jae Eui Shin

Myong Jae Lee

Jin Ah Jeong

Eun Hye Jang

Yeongran Yoo

In-Gyu Je

Sung Wook Kwon

Kyeojin Kim

Jaeho Heo

A-rang Im

Ji Hye Choi

Jung Woo Lee

Dami Lim

Jongmin Yoon

Hongchul Yoon

Jaeeun Ryu

Jungho Kim

Kyeong-A Kim

Ilji Jeong

Jinsun Kwon

Jooyun Lee

Seolhee Lee

Myongjae Lee

A-Rang Im

Jung-Eun Park

Te-Ik Sohn

Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.

GLP-1 receptor agonist and use thereof

The present disclosure provides CFTR modulator and phosphodiesterase 4 (PDE4) inhibitor compounds of the formula (Ia): and compositions including said compounds. The compounds can provide functionality for modulating CFTR, methods for treating an eye disease or disorder, and methods for treating CFTR-related indications. The present disclosure also provides methods of using said compounds and compositions for inhibiting PDE4 in a biological system or biological sample, for treating an inflammatory disease or disorder, and for treating other PDE4-related indications. Also provided are methods of preparing said compounds and compositions, and synthetic precursors of said compounds.

Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators

Growing community of inventors

Gyeonggi-do, South Korea

Changmok Oh